EUVIMED · CrossrefJournal
MMWR. Morbidity and Mortality Weekly Report
ISSN 0149-2195 · Centers for Disease Control MMWR Office
Latest articles
Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025
Notes from the Field: Dengue Outbreak — American Samoa, 2025–2026
Hantavirus Outbreak Caused by Andes Virus Linked to International Cruise Ship Travel — United States, 2026
Cutaneous Aspergillosis Among Extremely Preterm Neonates in Neonatal Intensive Care Units — Michigan and New York, 2023–2024
Notes from the Field: Use of Enhanced Surveillance to Detect Severe Group A Streptococcus Infections Among Persons Experiencing Homelessness — Missoula County, Montana, July 2024–September 2025
QuickStats: Percentage* of Children and Adolescents Aged 5–17 Years Who Had Ever Received a Diagnosis of Attention-Deficit/Hyperactivity Disorder, by Sex and Year — United States, 2019–2025
Characteristics of Sudden Unexpected Infant Deaths — United States, 2020–2024
Notes from the Field : Clinical Characteristics of Patients with Ebola Disease Caused by Bundibugyo Virus — Uganda, 2026
Buprenorphine Dispensed by Pharmacies and Administered in Emergency Departments in Urban and Rural Areas — United States, 2019–2025
Progress Toward Rubella and Congenital Rubella Syndrome Elimination — Worldwide, 2012–2024
Alpha-gal Immunoglobulin E Seroprevalence Among Blood Donors — 10 States, 2024–2025
Modeled Scenario Projections for the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026
Assessment of Risk to the U.S. Population from the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026
Notes from the Field: Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo and Uganda, May 2026
Characteristics of Patients Hospitalized with Measles During an Outbreak — West Texas, January–March 2025
Fatal Human Case of Highly Pathogenic Avian Influenza A(H5N5) in a Backyard Flock Owner — Washington, November 2025
Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025
Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 — Worldwide, November 2024–February 2026
Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026
COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years — United States, June 1, 2023–September 30, 2025
Respiratory Virus Activity — United States, July 1, 2024–June 30, 2025
Progress Toward Eradication of Dracunculiasis (Guinea Worm Disease) — Worldwide, January 2024–June 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants — 24 States, December 2024–April 2025
Influenza-Associated Pediatric Deaths — United States, 2024–25 Influenza Season
Interim Effectiveness Estimates of 2025 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Outpatient and Hospitalized Illness — Eight Southern Hemisphere Countries, March–September 2025
Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025
Influenza-Associated Hospitalizations During a High Severity Season — Influenza Hospitalization Surveillance Network, United States, 2024–25 Influenza Season
Drug Overdose Deaths Involving Stimulants ― United States, January 2018–June 2024
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025–26 Influenza Season
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
EUVIMED